| abstract |
A method of predicting patient response to cancer treatment, comprising: Measuring gene expression levels of a plurality of genes selected from the groups consisting of groups A, B and C defined below in a biological sample from a patient: a. Group A: Genes corresponding to transcripts identified by the following Unigene ID Nos. Hs.592692, Hs.633514, Hs.127126, Hs.334587, Hs.648626, Hs.646346, Hs.584803, Hs.567495, Hs.651126, Hs.478746, Hs.72550, Hs.154276 , Hs.233568, Hs.106861, Hs.414418, Hs.593565, Hs.235116, Hs.554791, Hs.226780, Hs.525549, Hs.536158, Hs.438489, Hs.643279, Hs.189772, Hs .78977, Hs.155983, Hs.612872, Hs.435933, Hs.489603, Hs.128959, Hs.335205, Hs.146406, Hs.596783, Hs.512973, Hs.461030, Hs.149983, Hs.464137 , Hs.292524, Hs.283749, Hs.287362, Hs.492203, Hs.250693, Hs.593232, Hs.590575, Hs.428214, Hs.523847, Hs.533712, Hs.44067, Hs.647072, Hs , Hs. 169,039, Hs. 542938, Hs. 632020, Hs. 642938, Hs.631930, Hs.148907, Hs.160556, Hs.126891, Hs.124011, Hs.524828 , Hs.4779, Hs.612872, Hs.233240, Hs.445030, Hs.460, Hs.112432, Hs.544738, Hs.530941, Hs.180903, Hs.76364, Hs.43627, Hs.643599, Hs 125038, Hs.131342, Hs.512767, Hs.631974, Hs.112873 and Hs.6217; b. Group B: Genes corresponding to transcripts identified by the following Unigene ID Nos. are connected: Hs.72550, Hs.528299, Hs.510078, ... |